Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 168

1.

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials.

Sax PE, Erlandson KM, Lake JE, McComsey GA, Orkin C, Esser S, Brown TT, Rockstroh JK, Wei X, Carter CC, Zhong L, Brainard DM, Melbourne K, Das M, Stellbrink HJ, Post FA, Waters L, Koethe JR.

Clin Infect Dis. 2019 Oct 14. pii: ciz999. doi: 10.1093/cid/ciz999. [Epub ahead of print]

PMID:
31606734
2.

Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen.

Rizzardini G, Gori A, Miralles C, Olalla J, Molina JM, Raffi F, Kumar P, Antinori A, Ramgopal M, Stellbrink HJ, Das M, Chu H, Ram R, Garner W, Shao Y, Chuck SK, Piontkowsky D, Haubrich RH.

AIDS. 2019 Aug 1;33(10):1583-1593. doi: 10.1097/QAD.0000000000002244.

PMID:
31305329
3.

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.

Stellbrink HJ, Arribas JR, Stephens JL, Albrecht H, Sax PE, Maggiolo F, Creticos C, Martorell CT, Wei X, Acosta R, Collins SE, Brainard D, Martin H.

Lancet HIV. 2019 Jun;6(6):e364-e372. doi: 10.1016/S2352-3018(19)30080-3. Epub 2019 May 5.

PMID:
31068272
4.

Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study.

Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, Corbelli GM, Estrada V, Geretti AM, Beloukas A, Raben D, Coll P, Antinori A, Nwokolo N, Rieger A, Prins JM, Blaxhult A, Weber R, Van Eeden A, Brockmeyer NH, Clarke A, Del Romero Guerrero J, Raffi F, Bogner JR, Wandeler G, Gerstoft J, Gutiérrez F, Brinkman K, Kitchen M, Ostergaard L, Leon A, Ristola M, Jessen H, Stellbrink HJ, Phillips AN, Lundgren J; PARTNER Study Group.

Lancet. 2019 Jun 15;393(10189):2428-2438. doi: 10.1016/S0140-6736(19)30418-0. Epub 2019 May 2.

5.

Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.

Gupta SK, Post FA, Arribas JR, Eron JJ Jr, Wohl DA, Clarke AE, Sax PE, Stellbrink HJ, Esser S, Pozniak AL, Podzamczer D, Waters L, Orkin C, Rockstroh JK, Mudrikova T, Negredo E, Elion RA, Guo S, Zhong L, Carter C, Martin H, Brainard D, SenGupta D, Das M.

AIDS. 2019 Jul 15;33(9):1455-1465. doi: 10.1097/QAD.0000000000002223.

6.

Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA.

Amele S, Peters L, Sluzhynska M, Yakovlev A, Scherrer A, Domingo P, Gerstoft J, Viard JP, Gisinger M, Flisiak R, Bhaghani S, Ristola M, Leen C, Jablonowska E, Wandeler G, Stellbrink H, Falconer K, D'Arminio Monforte A, Horban A, Rockstroh JK, Lundgren JD, Mocroft A; EuroSIDA study group.

HIV Med. 2019 Apr;20(4):264-273. doi: 10.1111/hiv.12711. Epub 2019 Feb 8.

PMID:
30734998
7.

Antiretroviral switch studies do matter.

Daar ES, Ruane P, DeJesus E, Stellbrink HJ, Molina JM.

Lancet HIV. 2018 Oct;5(10):e546. doi: 10.1016/S2352-3018(18)30259-5. Epub 2018 Oct 8. No abstract available.

PMID:
30319119
8.

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials.

Hagins D, Orkin C, Daar ES, Mills A, Brinson C, DeJesus E, Post FA, Morales-Ramirez J, Thompson M, Osiyemi O, Rashbaum B, Stellbrink HJ, Martorell C, Liu H, Liu YP, Porter D, Collins SE, SenGupta D, Das M.

HIV Med. 2018 Nov;19(10):724-733. doi: 10.1111/hiv.12664. Epub 2018 Aug 12.

9.

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

Molina JM, Ward D, Brar I, Mills A, Stellbrink HJ, López-Cortés L, Ruane P, Podzamczer D, Brinson C, Custodio J, Liu H, Andreatta K, Martin H, Cheng A, Quirk E.

Lancet HIV. 2018 Jul;5(7):e357-e365. doi: 10.1016/S2352-3018(18)30092-4. Epub 2018 Jun 18. Erratum in: Lancet HIV. 2018 Jun 22;:.

PMID:
29925489
10.

Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study.

Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Stephan C, Rockstroh J, Giacomelli A, Vera J, Bernardino JI, Winston A, Saumoy M, Gras J, Katlama C, Pozniak AL; European Network for AIDS Treatment 022 (NEAT022) Study Group .

Clin Infect Dis. 2019 Feb 1;68(4):597-606. doi: 10.1093/cid/ciy505.

PMID:
29912307
11.

Cabotegravir: its potential for antiretroviral therapy and preexposure prophylaxis.

Stellbrink HJ, Hoffmann C.

Curr Opin HIV AIDS. 2018 Jul;13(4):334-340. doi: 10.1097/COH.0000000000000480. Review.

PMID:
29746267
12.

Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk.

Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Pozniak AL; NEAT022 Study Group*.

AIDS. 2017 Nov 28;31(18):2503-2514. doi: 10.1097/QAD.0000000000001675.

13.

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.

Sax PE, Pozniak A, Montes ML, Koenig E, DeJesus E, Stellbrink HJ, Antinori A, Workowski K, Slim J, Reynes J, Garner W, Custodio J, White K, SenGupta D, Cheng A, Quirk E.

Lancet. 2017 Nov 4;390(10107):2073-2082. doi: 10.1016/S0140-6736(17)32340-1. Epub 2017 Aug 31.

PMID:
28867499
14.

Reply to Letter 'Morning dosing for dolutegravir-related insomnia and sleep disorders' by Capetti et al.

Hoffmann C, Welz T, Sabranski M, Kolb M, Wolf E, Stellbrink HJ, Wyen C.

HIV Med. 2018 May;19(5):e60-e61. doi: 10.1111/hiv.12539. Epub 2017 Aug 29. No abstract available.

PMID:
28851009
15.

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.

Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, Eron JJ, Yazdanpanah Y, Podzamczer D, Lutz T, Angel JB, Richmond GJ, Clotet B, Gutierrez F, Sloan L, Clair MS, Murray M, Ford SL, Mrus J, Patel P, Crauwels H, Griffith SK, Sutton KC, Dorey D, Smith KY, Williams PE, Spreen WR.

Lancet. 2017 Sep 23;390(10101):1499-1510. doi: 10.1016/S0140-6736(17)31917-7. Epub 2017 Jul 24.

PMID:
28750935
16.

[Treatment of HIV-infected patients: metabolism, bone, cardiovascular - what is part of routine care?]

Stellbrink HJ.

MMW Fortschr Med. 2017 Jun;159(Suppl 2):14-23. doi: 10.1007/s15006-017-9047-1. German. No abstract available.

PMID:
28597280
17.

Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort.

Borges ÁH, Hoy J, Florence E, Sedlacek D, Stellbrink HJ, Uzdaviniene V, Tomazic J, Gargalianos-Kakolyris P, Schmid P, Orkin C, Pedersen C, Leen C, Pradier C, Mulcahy F, Ridolfo AL, Staub T, Maltez F, Weber R, Flamholc L, Kyselyova G, Lundgren JD, Mocroft A; for EuroSIDA.

Clin Infect Dis. 2017 May 15;64(10):1413-1421. doi: 10.1093/cid/cix167. Erratum in: Clin Infect Dis. 2017 Oct 15;65(8):1431-1433.

PMID:
28329090
18.

The "Choosing Wisely" initiative in infectious diseases.

Lehmann C, Berner R, Bogner JR, Cornely OA, de With K, Herold S, Kern WV, Lemmen S, Pletz MW, Ruf B, Salzberger B, Stellbrink HJ, Suttorp N, Ullmann AJ, Fätkenheuer G, Jung N.

Infection. 2017 Jun;45(3):263-268. doi: 10.1007/s15010-017-0997-0. Epub 2017 Mar 13. Review.

PMID:
28290130
19.

Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.

DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A, Mills A, Martorell CT, de Wet J, Stellbrink HJ, Molina JM, Post FA, Valero IP, Porter D, Liu Y, Cheng A, Quirk E, SenGupta D, Cao H.

Lancet HIV. 2017 May;4(5):e205-e213. doi: 10.1016/S2352-3018(17)30032-2. Epub 2017 Mar 2.

PMID:
28259776
20.

Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients.

Hoffmann C, Welz T, Sabranski M, Kolb M, Wolf E, Stellbrink HJ, Wyen C.

HIV Med. 2017 Jan;18(1):56-63. doi: 10.1111/hiv.12468. Epub 2016 Nov 10.

21.

Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study.

Llibre JM, Cozzi-Lepri A, Pedersen C, Ristola M, Losso M, Mocroft A, Mitsura V, Falconer K, Maltez F, Beniowski M, Vullo V, Hassoun G, Kuzovatova E, Szlavik J, Kuznetsova A, Stellbrink HJ, Duvivier C, Edwards S, Laut K, Paredes R; EuroSIDA Study.

Medicine (Baltimore). 2016 Oct;95(40):e5020.

22.

HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe.

Ingiliz P, Martin TC, Rodger A, Stellbrink HJ, Mauss S, Boesecke C, Mandorfer M, Bottero J, Baumgarten A, Bhagani S, Lacombe K, Nelson M, Rockstroh JK; NEAT study group.

J Hepatol. 2017 Feb;66(2):282-287. doi: 10.1016/j.jhep.2016.09.004. Epub 2016 Sep 17.

PMID:
27650285
23.

Analysis of contemporary HIV/AIDS health care costs in Germany: Driving factors and distribution across antiretroviral therapy lines.

Treskova M, Kuhlmann A, Bogner J, Hower M, Heiken H, Stellbrink HJ, Mahlich J, Schulenburg JM, Stoll M.

Medicine (Baltimore). 2016 Jun;95(26):e3961. doi: 10.1097/MD.0000000000003961.

24.

Which HIV patients should be screened for osteoporosis: an international perspective.

Alvarez E, Belloso WH, Boyd MA, Inkaya AÇ, Hsieh E, Kambugu A, Kaminski G, Martinez E, Stellbrink HJ, Walmsley S, Brown TT, Mallon PW.

Curr Opin HIV AIDS. 2016 May;11(3):268-76. doi: 10.1097/COH.0000000000000269. Review.

PMID:
26895510
25.

Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment.

Stellbrink HJ, Le Fevre E, Carr A, Saag MS, Mukwaya G, Nozza S, Valluri SR, Vourvahis M, Rinehart AR, McFadyen L, Fichtenbaum C, Clark A, Craig C, Fang AF, Heera J.

AIDS. 2016 May 15;30(8):1229-38. doi: 10.1097/QAD.0000000000001058.

26.

German-Austrian guidelines on anal dysplasia and anal cancer in HIV-positive individuals: prevention, diagnosis, and treatment.

Esser S, Kreuter A, Oette M, Gingelmaier A, Mosthaf F, Sautter-Bihl ML, Jongen J, Brockmeyer NH, Eldering G, Swoboda J, Postel N, Degen O, Schalk H, Jessen A, Knechten H, Thoden J, Stellbrink HJ, Schafberger A, Wieland U.

J Dtsch Dermatol Ges. 2015 Dec;13(12):1302-19. doi: 10.1111/ddg.12726. No abstract available.

PMID:
26612810
27.

Dual treatment of acute HCV infection in HIV co-infection: influence of HCV genotype upon treatment outcome.

Boesecke C, Ingiliz P, Reiberger T, Stellbrink HJ, Bhagani S, Page E, Mauss S, Lutz T, Voigt E, Guiguet M, Valantin MA, Baumgarten A, Nelson M, Vogel M, Rockstroh JK; NEAT Study Group.

Infection. 2016 Feb;44(1):93-101.

PMID:
26481253
28.

HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans.

Spinner CD, Boesecke C, Zink A, Jessen H, Stellbrink HJ, Rockstroh JK, Esser S.

Infection. 2016 Apr;44(2):151-8. doi: 10.1007/s15010-015-0850-2. Epub 2015 Oct 15. Review.

PMID:
26471511
29.

From pills to patients: an evaluation of data sources to determine the number of people living with HIV who are receiving antiretroviral therapy in Germany.

Schmidt D, Kollan C, Stoll M, Stellbrink HJ, Plettenberg A, Fätkenheuer G, Bergmann F, Bogner JR, van Lunzen J, Rockstroh J, Esser S, Jensen BE, Horst HA, Fritzsche C, Kühne A, an der Heiden M, Hamouda O, Bartmeyer B; ClinSurv Study Group.

BMC Public Health. 2015 Mar 17;15:252. doi: 10.1186/s12889-015-1598-4.

30.

[Postexposure prophylaxis in daily clinical practice].

Küpper MF, Stellbrink HJ, Kern WV, Müller MC.

Dtsch Med Wochenschr. 2015 Apr;140(7):485-8. doi: 10.1055/s-0041-101188. Epub 2015 Mar 31. German.

PMID:
25826030
31.

Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 Δ32.

Henrich TJ, Hanhauser E, Hu Z, Stellbrink HJ, Noah C, Martin JN, Deeks SG, Kuritzkes DR, Pereyra F.

AIDS. 2015 May 15;29(8):867-76. doi: 10.1097/QAD.0000000000000629.

32.

Protease Inhibitors and Renal Function in Patients with HIV Infection: a Systematic Review.

Bagnis CI, Stellbrink HJ.

Infect Dis Ther. 2015 Jan 8. [Epub ahead of print]

33.

Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-NNRTI subgroup analysis.

Stellbrink HJ, Antinori A, Pozniak A, Flamm J, Bredeek F, Patel K, Garner W, Piontkowsky D.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19793. doi: 10.7448/IAS.17.4.19793. eCollection 2014.

34.

144-week outcomes of lopinavir/ritonavir (LPV/r)-based first-line ART in 1,409 HIV-infected patients: data from the German STAR/STELLA cohort.

Wolf E, Trein A, Baumgarten A, Stephan C, Jaeger H, Hillenbrand H, Koeppe S, Lutz T, Koenig B, Stellbrink HJ.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19770. doi: 10.7448/IAS.17.4.19770. eCollection 2014.

35.

Intermittent viraemia and immune reconstitution in patients with more than 10-15 years of antiretroviral therapy: baseline values still matter.

Erdbeer G, Sabranski M, Sonntag I, Stoehr A, Horst HA, Plettenberg A, Schewe K, Unger S, Stellbrink HJ, Fenske S, Hoffmann C.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19689. doi: 10.7448/IAS.17.4.19689. eCollection 2014.

36.

Everything fine so far? Physical and mental health in HIV-infected patients with virological success and long-term exposure to antiretroviral therapy.

Erdbeer G, Sabranski M, Sonntag I, Stoehr A, Horst HA, Plettenberg A, Schewe K, Unger S, Stellbrink HJ, Fenske S, Hoffmann C.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19673. doi: 10.7448/IAS.17.4.19673. eCollection 2014.

37.

Ongoing epidemic of lymphogranuloma venereum in HIV-positive men who have sex with men: how symptoms should guide treatment.

Mohrmann G, Noah C, Sabranski M, Sahly H, Stellbrink HJ.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19657. doi: 10.7448/IAS.17.4.19657. eCollection 2014.

38.

Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study.

Berkowitz EM, Moyle G, Stellbrink HJ, Schürmann D, Kegg S, Stoll M, El Idrissi M, Oostvogels L, Heineman TC; Zoster-015 HZ/su Study Group.

J Infect Dis. 2015 Apr 15;211(8):1279-87. doi: 10.1093/infdis/jiu606. Epub 2014 Nov 3.

39.

[Cost of Illness of HIV Patients under Anteretroviral Therapy in Germany - Results of the 48-Week Interim Analysis of the Prospective Multicentre Observational Study 'CORSAR'].

Kuhlmann A, Mittendorf T, Hower M, Heiken H, Gerschmann S, Klauke S, Lutz T, Bogner J, Degen O, van Lunzen J, Bachmann C, Stellbrink HJ, Schmidt W, Leistner I, Mahlich J, Ranneberg B, Stoll M.

Gesundheitswesen. 2015 Jun;77(6):e133-42. doi: 10.1055/s-0034-1381993. Epub 2014 Sep 23. German.

PMID:
25247761
40.

Estimating trends in the proportion of transmitted and acquired HIV drug resistance in a long term observational cohort in Germany.

Schmidt D, Kollan C, Fätkenheuer G, Schülter E, Stellbrink HJ, Noah C, Jensen BE, Stoll M, Bogner JR, Eberle J, Meixenberger K, Kücherer C, Hamouda O, Bartmeyer B; ClinSurv-HIV Drug Resistance Study Group in CHAIN.

PLoS One. 2014 Aug 22;9(8):e104474. doi: 10.1371/journal.pone.0104474. eCollection 2014.

41.

Peginterferon-alfa mono-therapy in the treatment of acute hepatitis C in HIV-infection.

Boesecke C, van Assen S, Stellbrink HJ, Baumgarten A, Ingiliz P, Strassburg CP, Schwarze-Zander C, Wasmuth JC, Hoepelman AI, Rockstroh JK, Arends JE.

J Viral Hepat. 2014 Nov;21(11):780-5. doi: 10.1111/jvh.12272. Epub 2014 Jul 9.

PMID:
25040149
42.

Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial.

Pozniak A, Markowitz M, Mills A, Stellbrink HJ, Antela A, Domingo P, Girard PM, Henry K, Nguyen T, Piontkowsky D, Garner W, White K, Guyer B.

Lancet Infect Dis. 2014 Jul;14(7):590-9. doi: 10.1016/S1473-3099(14)70796-0. Epub 2014 Jun 5.

PMID:
24908550
43.

Morbidity in older HIV-infected patients: impact of long-term antiretroviral use.

Guaraldi G, Prakash M, Moecklinghoff C, Stellbrink HJ.

AIDS Rev. 2014 Apr-Jun;16(2):75-89. Review.

PMID:
24759453
44.

Multiple hepatitis C virus (HCV) reinfections in HIV-positive men who have sex with men: no influence of HCV genotype switch or interleukin-28B genotype on spontaneous clearance.

Ingiliz P, Krznaric I, Stellbrink HJ, Knecht G, Lutz T, Noah C, Stocker H, Obermeier M, Dupke S, Boesecke C, Rockstroh JK, Baumgarten A, Hoffmann C.

HIV Med. 2014 Jul;15(6):355-61. doi: 10.1111/hiv.12127. Epub 2014 Feb 24.

45.

Antiviral activity, pharmacokinetics, and safety of the HIV-1 protease inhibitor TMC310911, coadministered with ritonavir, in treatment-naive HIV-1-infected patients.

Stellbrink HJ, Arastéh K, Schürmann D, Stephan C, Dierynck I, Smyej I, Hoetelmans RM, Truyers C, Meyvisch P, Jacquemyn B, Mariën K, Simmen K, Verloes R.

J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):283-9. doi: 10.1097/QAI.0000000000000003.

PMID:
24121756
46.

Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066).

Thoden J, Potthoff A, Bogner JR, Brockmeyer NH, Esser S, Grabmeier-Pfistershammer K, Haas B, Hahn K, Härter G, Hartmann M, Herzmann C, Hutterer J, Jordan AR, Lange C, Mauss S, Meyer-Olson D, Mosthaf F, Oette M, Reuter S, Rieger A, Rosenkranz T, Ruhnke M, Schaaf B, Schwarze S, Stellbrink HJ, Stocker H, Stoehr A, Stoll M, Träder C, Vogel M, Wagner D, Wyen C, Hoffmann C; Deutsche AIDS Gesellschaft; Österreichische AIDS-Gesellschaft.

Infection. 2013 Sep;41 Suppl 2:S91-115. doi: 10.1007/s15010-013-0504-1. Epub 2013 Sep 14.

47.

Variation in IFNL4 genotype and response to interferon-based therapy of hepatitis C in HIV-positive patients with acute and chronic hepatitis C.

Krämer B, Nischalke HD, Boesecke C, Ingiliz P, Voigt E, Mauss S, Stellbrink HJ, Baumgarten A, Rockstroh JK, Spengler U, Nattermann J.

AIDS. 2013 Nov 13;27(17):2817-9. doi: 10.1097/01.aids.0000433234.78807.54.

PMID:
23939236
48.

96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.

Moyle GJ, Stellbrink HJ, Compston J, Orkin C, Arribas JR, Domingo P, Granier C, Pearce H, Sedani S, Gartland M; ASSERT Team.

Antivir Ther. 2013;18(7):905-13. doi: 10.3851/IMP2667. Epub 2013 Jul 31.

PMID:
23899468
49.

High rates of quinolone-resistant strains of Shigella sonnei in HIV-infected MSM.

Hoffmann C, Sahly H, Jessen A, Ingiliz P, Stellbrink HJ, Neifer S, Schewe K, Dupke S, Baumgarten A, Kuschel A, Krznaric I.

Infection. 2013 Oct;41(5):999-1003. doi: 10.1007/s15010-013-0501-4. Epub 2013 Jul 13.

PMID:
23852945
50.

Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study.

Stellbrink HJ, Reynes J, Lazzarin A, Voronin E, Pulido F, Felizarta F, Almond S, St Clair M, Flack N, Min S; SPRING-1 Team.

AIDS. 2013 Jul 17;27(11):1771-8. doi: 10.1097/QAD.0b013e3283612419.

Supplemental Content

Loading ...
Support Center